Data analysis with Shapley values for automatic subject selection in Alzheimer’s disease data sets using interpretable machine learning
For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneou...
Saved in:
Published in | Alzheimer's research & therapy Vol. 13; no. 1; pp. 155 - 30 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
15.09.2021
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification.
An ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation.
The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set.
The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements. |
---|---|
AbstractList | Background For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer’s disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. Methods An ML workflow was developed and trained for a subset of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. Results The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. Conclusion The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements. Background For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. Methods An ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. Results The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. Conclusion The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE [epsilon]4 (ApoE [epsilon]4) alleles, cognitive test results, and volumetric MRI measurements. Keywords: Machine learning, Data Shapley, Interpretability, AIBL, ADNI, Shapley values, Mild cognitive impairment, Alzheimer's disease For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. An ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements. Abstract Background For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer’s disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. Methods An ML workflow was developed and trained for a subset of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. Results The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. Conclusion The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements. For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification. An ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation. The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set. The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE [epsilon]4 (ApoE [epsilon]4) alleles, cognitive test results, and volumetric MRI measurements. For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification.BACKGROUNDFor the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will prospectively develop Alzheimer's disease (AD). Machine learning (ML) is suitable to improve early AD prediction. The etiology of AD is heterogeneous, which leads to high variability in disease patterns. Further variability originates from multicentric study designs, varying acquisition protocols, and errors in the preprocessing of magnetic resonance imaging (MRI) scans. The high variability makes the differentiation between signal and noise difficult and may lead to overfitting. This article examines whether an automatic and fair data valuation method based on Shapley values can identify the most informative subjects to improve ML classification.An ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation.METHODSAn ML workflow was developed and trained for a subset of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. The validation was executed for an independent ADNI test set and for the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) cohort. The workflow included volumetric MRI feature extraction, feature selection, sample selection using Data Shapley, random forest (RF), and eXtreme Gradient Boosting (XGBoost) for model training as well as Kernel SHapley Additive exPlanations (SHAP) values for model interpretation.The RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set.RESULTSThe RF models, which excluded 134 of the 467 training subjects based on their RF Data Shapley values, outperformed the base models that reached a mean accuracy of 62.64% by 5.76% (3.61 percentage points) for the independent ADNI test set. The XGBoost base models reached a mean accuracy of 60.00% for the AIBL data set. The exclusion of those 133 subjects with the smallest RF Data Shapley values could improve the classification accuracy by 2.98% (1.79 percentage points). The cutoff values were calculated using an independent validation set.The Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements.CONCLUSIONThe Data Shapley method was able to improve the mean accuracies for the test sets. The most informative subjects were associated with the number of ApolipoproteinE ε4 (ApoE ε4) alleles, cognitive test results, and volumetric MRI measurements. |
ArticleNumber | 155 |
Audience | Academic |
Author | Friedrich, Christoph M. Bloch, Louise |
Author_xml | – sequence: 1 givenname: Louise orcidid: 0000-0001-7540-4980 surname: Bloch fullname: Bloch, Louise – sequence: 2 givenname: Christoph M. orcidid: 0000-0001-7906-0038 surname: Friedrich fullname: Friedrich, Christoph M. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34526114$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1u1TAQhSNURH_gBVggS0iITYqd2ImzQarKX6VKLIC1NXEmN75y4ovttCortjwCr8eT4PS20FshlMVE9jmfPeNzmO1NbsIse8roMWOyehVYyRqR04LllMq6yfmD7IDVQuYNa8q9O__72WEIa0qrqpD8UbZfclFUjPGD7McbiEBgAnsVTCCXJg7k0wAbi1fkAuyMgfTOE5ijGyEaTcLcrlFHEtCmYtxEzERO7LcBzYj-1_efgXQmIAQk3YIOGAOZg5lWSRjRbzxGaC2SEfRgJiQWwU9p-3H2sAcb8MlNPcq-vHv7-fRDfv7x_dnpyXmuRcNjjiXrsMemKFjVp9ZApyJ0S6loWy5LlAUv6qaWZVNRzqkoRdVozQUUmlGg5VF2tuV2DtZq480I_ko5MOp6wfmVAp86taiERGwL0bFaVlygAJSialsGrOkqxrvEer1lbeZ2xE7jFD3YHejuzmQGtXIXSnLOKyYT4OUNwLuvadhRjSZotBYmdHNQhahLXopGLPd-fk-6drNPD3et4ryUktV_VStIDZipd-lcvUDVSVVLmloRTVId_0OVvg5Ho1PKepPWdwwv7hgGBBuH4Oy8BCDsCp_dncifUdwmLgnkVqC9C8Fjr7SJsHDSFYxVjKol3GobbpXCra7DrRZrcc96S_-P6Tfvmfx8 |
CitedBy_id | crossref_primary_10_3390_diagnostics15050612 crossref_primary_10_1007_s11306_022_01937_0 crossref_primary_10_1016_j_compbiomed_2024_108029 crossref_primary_10_1007_s42979_022_01371_y crossref_primary_10_3389_fpubh_2022_940182 crossref_primary_10_1016_j_jstrokecerebrovasdis_2023_107354 crossref_primary_10_3233_JAD_220776 crossref_primary_10_3390_neurolint16060098 crossref_primary_10_3390_jpm14080811 crossref_primary_10_1186_s12938_023_01107_w crossref_primary_10_1007_s42600_024_00394_z crossref_primary_10_1021_jasms_3c00403 crossref_primary_10_1016_j_drudis_2024_104280 crossref_primary_10_1007_s12559_023_10153_4 crossref_primary_10_1007_s11682_025_00984_0 crossref_primary_10_3389_fcvm_2024_1419551 crossref_primary_10_1038_s41598_024_82544_y crossref_primary_10_1186_s12911_024_02556_6 crossref_primary_10_1016_j_bbe_2022_06_007 crossref_primary_10_3390_jpm12040550 crossref_primary_10_1177_15333175241275215 crossref_primary_10_3389_fnagi_2025_1542514 crossref_primary_10_3390_s24155024 crossref_primary_10_1186_s12958_024_01271_1 crossref_primary_10_1371_journal_pone_0285416 crossref_primary_10_3390_s22187037 crossref_primary_10_2196_68066 crossref_primary_10_3390_diagnostics14182049 crossref_primary_10_3390_jpm12010043 |
Cites_doi | 10.1038/nrneurol.2009.215 10.1002/hbm.20934 10.1023/A:1010933404324 10.1007/BF00994018 10.1016/j.neurobiolaging.2003.12.007 10.1016/j.media.2020.101694 10.1212/WNL.34.7.939 10.5220/0010211300870099 10.1186/s13195-018-0455-y 10.1162/jocn.2009.21407 10.1111/j.1365-2796.2004.01380.x 10.1073/pnas.90.5.1977 10.1109/ICDM.2008.17 10.1016/j.jalz.2016.10.006 10.3389/fnagi.2019.00220 10.2307/3001968 10.1145/335191.335388 10.1016/j.neuroimage.2015.01.048 10.1021/ci0342472 10.1159/000320988 10.1186/s13195-020-00716-0 10.1038/srep46263 10.1212/01.WNL.0000110315.26026.EF 10.1186/s12916-018-1122-7 10.1093/brain/awaa137 10.1159/000072920 10.1016/j.dadm.2015.11.002 10.1002/jmri.21049 10.1214/aoms/1177730491 10.1136/gpsych-2018-100005 10.1136/bmj.b158 10.1101/2019.12.12.874784 10.1109/ACCESS.2019.2932769 10.1016/j.ins.2017.11.036 10.1007/978-3-319-47578-3 10.1007/s10548-012-0246-x 10.1016/j.pscychresns.2011.06.014 10.1002/widm.1379 10.1186/s13024-018-0299-8 10.1145/2939672.2939785 10.1109/CVPR.2017.369 10.1016/j.neuroimage.2018.08.042 10.1515/9781400881970-018 10.1016/S0896-6273(02)00569-X 10.2307/1268249 10.1002/hbm.25398 10.1007/s11263-015-0816-y 10.1038/s41598-018-29295-9 10.1067/mhj.2002.123579 10.1016/j.neuroimage.2006.01.021 10.1613/jair.1.12125 10.1002/alz.12068 10.1109/IJCNN.2011.6033571 10.1038/s41598-021-87762-2 10.1016/j.neuroimage.2004.03.040 10.1016/j.neuroimage.2012.01.021 10.1016/j.jalz.2011.03.003 10.1126/science.8346443 10.1007/s11682-018-9831-2 10.1007/s13167-020-00216-z 10.1038/nature14539 10.1016/j.neuroimage.2012.02.084 10.18653/v1/n16-3020 10.1212/WNL.0b013e3181cb3e25 10.1136/jnnp.2010.231555 10.1145/2950109 10.1007/978-3-319-59050-912 10.3233/JAD-170261 10.1109/CVPR.2016.90 10.1017/S1041610209009405 10.1038/srep45269 10.1371/journal.pone.0066367 10.1371/journal.pone.0236868 10.1016/j.dadm.2018.07.004 10.1016/j.jalz.2010.03.004 |
ContentType | Journal Article |
Copyright | 2021. The Author(s). COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
Copyright_xml | – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
CorporateAuthor | for the Alzheimer’s Disease Neuroimaging Initiative Alzheimer’s Disease Neuroimaging Initiative |
CorporateAuthor_xml | – name: for the Alzheimer’s Disease Neuroimaging Initiative – name: Alzheimer’s Disease Neuroimaging Initiative |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s13195-021-00879-4 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1758-9193 |
EndPage | 30 |
ExternalDocumentID | oai_doaj_org_article_58eeb25d178645e5ae856bb1a19d614d PMC8444618 A678017859 34526114 10_1186_s13195_021_00879_4 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | Australia Germany |
GeographicLocations_xml | – name: Australia – name: Germany |
GrantInformation_xml | – fundername: CIHR – fundername: NIA NIH HHS grantid: U01 AG024904 |
GroupedDBID | --- 0R~ 23M 2WC 53G 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFS ACIHN ACJQM ACUHS ADBBV ADUKV AEAQA AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION DIK E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HZ~ IAO IEA IHR IHW INH INR ITC KQ8 M1P M~E O5R O5S O9- OK1 P2P P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SBL SOJ TR2 TUS UKHRP CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c594t-e31defe92216f193ac6f15cb005bb483e82427978396044053569cc45a2c10a03 |
IEDL.DBID | 7X7 |
ISSN | 1758-9193 |
IngestDate | Wed Aug 27 01:30:54 EDT 2025 Thu Aug 21 17:38:06 EDT 2025 Fri Jul 11 07:44:12 EDT 2025 Fri Jul 25 04:23:24 EDT 2025 Tue Jun 17 21:15:26 EDT 2025 Tue Jun 10 20:37:34 EDT 2025 Thu May 22 21:15:47 EDT 2025 Mon Jul 21 06:00:44 EDT 2025 Tue Jul 01 02:38:51 EDT 2025 Thu Apr 24 23:00:13 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | ADNI Shapley values Alzheimer’s disease Interpretability Mild cognitive impairment Machine learning AIBL Data Shapley |
Language | English |
License | 2021. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c594t-e31defe92216f193ac6f15cb005bb483e82427978396044053569cc45a2c10a03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-7540-4980 0000-0001-7906-0038 |
OpenAccessLink | https://www.proquest.com/docview/2574438817?pq-origsite=%requestingapplication% |
PMID | 34526114 |
PQID | 2574438817 |
PQPubID | 2040174 |
PageCount | 30 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_58eeb25d178645e5ae856bb1a19d614d pubmedcentral_primary_oai_pubmedcentral_nih_gov_8444618 proquest_miscellaneous_2573435950 proquest_journals_2574438817 gale_infotracmisc_A678017859 gale_infotracacademiconefile_A678017859 gale_healthsolutions_A678017859 pubmed_primary_34526114 crossref_citationtrail_10_1186_s13195_021_00879_4 crossref_primary_10_1186_s13195_021_00879_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-09-15 |
PublicationDateYYYYMMDD | 2021-09-15 |
PublicationDate_xml | – month: 09 year: 2021 text: 2021-09-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Alzheimer's research & therapy |
PublicationTitleAlternate | Alzheimers Res Ther |
PublicationYear | 2021 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | 879_CR14 SM Lundberg (879_CR44) 2017 CC Aggarwal (879_CR16) 2017 M Kusy (879_CR26) 2018; 430-431 G Van Rossum (879_CR40) 2009 B Winblad (879_CR47) 2004; 256 C Birkenbihl (879_CR78) 2020; 11 879_CR19 C Patterson (879_CR2) 2018 879_CR18 O Russakovsky (879_CR33) 2015; 115 DL Beekley (879_CR88) 2004; 18 J Cao (879_CR3) 2018; 13 B Duraisamy (879_CR25) 2018; 13 S Tang (879_CR37) 2021; 11 I Arevalo-Rodriguez (879_CR71) 2015; 3 T Schlegl (879_CR22) 2017 G Stiglic (879_CR83) 2020; 10 F Wilcoxon (879_CR49) 1945; 1 EE Bron (879_CR82) 2015; 111 MW Weiner (879_CR53) 2017; 13 DM Hawkins (879_CR13) 2004; 44 CG Northcutt (879_CR32) 2021; 70 RD Cook (879_CR41) 1977; 19 LS Elias-Sonnenschein (879_CR70) 2011; 82 KA Ellis (879_CR45) 2009; 21 M Dlugaj (879_CR85) 2010; 30 T Jo (879_CR9) 2019; 11 LS Shapley (879_CR36) 1953 O Pelka (879_CR79) 2020; 15 A Schmermund (879_CR86) 2002; 144 879_CR23 L An (879_CR30) 2017; 7 SP Poulin (879_CR64) 2011; 194 cr-split#-879_CR15.1 879_CR20 H Yang (879_CR72) 2019; 32 cr-split#-879_CR15.2 H Wang (879_CR24) 2019; 7 RS Desikan (879_CR55) 2006; 31 C Cortes (879_CR31) 1995; 20 F Pedregosa (879_CR59) 2011; 12 E Lawrence (879_CR77) 2017; 59 Alzheimer’s Association (879_CR1) 2020; 16 A Burns (879_CR5) 2009; 338 879_CR34 B Fischl (879_CR56) 2002; 33 S Qiu (879_CR80) 2020; 143 WJ Strittmatter (879_CR69) 1993; 90 CR Jack Jr. (879_CR51) 2008; 27 E Corder (879_CR68) 1993; 261 RC Petersen (879_CR27) 2010; 74 C Ledig (879_CR67) 2018; 8 C D’Urso (879_CR17) 2016; 7 Y LeCun (879_CR35) 2015; 521 879_CR39 879_CR38 D Ferreira (879_CR11) 2017; 7 DS Marcus (879_CR87) 2010; 22 L Breiman (879_CR42) 2001; 45 H Fröhlich (879_CR76) 2018; 16 E Pellegrini (879_CR8) 2018; 10 M Reuter (879_CR57) 2012; 61 E Westman (879_CR58) 2012; 26 Y Zhang (879_CR66) 2013; 8 T Chen (879_CR43) 2016 CR Jack (879_CR74) 2004; 62 879_CR84 M Dadar (879_CR12) 2021; 42 H Tabatabaei-Jafari (879_CR65) 2015; 1 CR Jack (879_CR52) 2010; 6 PM Thompson (879_CR73) 2004; 22 RA Sperling (879_CR4) 2011; 7 SG Mueller (879_CR62) 2010; 31 HB Mann (879_CR50) 1947; 18 D Shigemizu (879_CR6) 2020; 12 879_CR48 B Fischl (879_CR54) 2012; 62 M Ribeiro (879_CR60) 2016 L deToledo-Morrell (879_CR63) 2004; 25 3C study group (879_CR28) 2003; 22 E Adeli-Mosabbeb (879_CR29) 2015 GB Frisoni (879_CR61) 2010; 6 G Devi (879_CR10) 2018; 10 cr-split#-879_CR21.2 J Samper-González (879_CR75) 2018; 183 cr-split#-879_CR21.1 879_CR81 G McKhann (879_CR46) 1984; 34 J Wen (879_CR7) 2020; 63 |
References_xml | – volume: 6 start-page: 67 issue: 2 year: 2010 ident: 879_CR61 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2009.215 – volume: 31 start-page: 1339 issue: 9 year: 2010 ident: 879_CR62 publication-title: Hum Brain Mapp doi: 10.1002/hbm.20934 – volume-title: World Alzheimer Report 2018 - The State of the Art of Dementia Research: New Frontiers year: 2018 ident: 879_CR2 – volume: 45 start-page: 5 issue: 1 year: 2001 ident: 879_CR42 publication-title: Mach Learn doi: 10.1023/A:1010933404324 – volume: 20 start-page: 273 issue: 3 year: 1995 ident: 879_CR31 publication-title: Mach Learn doi: 10.1007/BF00994018 – volume: 25 start-page: 1197 issue: 9 year: 2004 ident: 879_CR63 publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2003.12.007 – volume: 63 start-page: 101694 year: 2020 ident: 879_CR7 publication-title: Med Image Anal doi: 10.1016/j.media.2020.101694 – volume: 34 start-page: 939 issue: 7 year: 1984 ident: 879_CR46 publication-title: Neurology doi: 10.1212/WNL.34.7.939 – ident: 879_CR39 doi: 10.5220/0010211300870099 – volume: 10 start-page: 122 issue: 1 year: 2018 ident: 879_CR10 publication-title: Alzheimers Res Ther doi: 10.1186/s13195-018-0455-y – volume: 22 start-page: 2677 issue: 12 year: 2010 ident: 879_CR87 publication-title: J Cogn Neurosci doi: 10.1162/jocn.2009.21407 – volume: 256 start-page: 240 issue: 3 year: 2004 ident: 879_CR47 publication-title: J Intern Med doi: 10.1111/j.1365-2796.2004.01380.x – volume: 90 start-page: 1977 issue: 5 year: 1993 ident: 879_CR69 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.90.5.1977 – ident: 879_CR18 doi: 10.1109/ICDM.2008.17 – volume: 13 start-page: 561 issue: 5 year: 2017 ident: 879_CR53 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2016.10.006 – volume: 11 start-page: 220 year: 2019 ident: 879_CR9 publication-title: Front Aging Neurosci doi: 10.3389/fnagi.2019.00220 – volume: 1 start-page: 80 issue: 6 year: 1945 ident: 879_CR49 publication-title: Biometrics doi: 10.2307/3001968 – ident: 879_CR20 doi: 10.1145/335191.335388 – volume-title: Advances in Neural Information Processing Systems (NIPS 2015): 7-12 December 2015; Montreal, Canada year: 2015 ident: 879_CR29 – ident: #cr-split#-879_CR15.2 – ident: 879_CR81 – volume: 111 start-page: 562 year: 2015 ident: 879_CR82 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2015.01.048 – volume: 44 start-page: 1 issue: 1 year: 2004 ident: 879_CR13 publication-title: J Chem Inf Comput Sci doi: 10.1021/ci0342472 – volume: 30 start-page: 362 issue: 4 year: 2010 ident: 879_CR85 publication-title: Dement. Geriatr Cogn Disord doi: 10.1159/000320988 – volume: 12 start-page: 145 issue: 1 year: 2020 ident: 879_CR6 publication-title: Alzheimers Res Ther doi: 10.1186/s13195-020-00716-0 – volume: 7 start-page: 46263 issue: 1 year: 2017 ident: 879_CR11 publication-title: Sci Rep doi: 10.1038/srep46263 – volume: 62 start-page: 591 issue: 4 year: 2004 ident: 879_CR74 publication-title: Neurology doi: 10.1212/01.WNL.0000110315.26026.EF – volume: 16 start-page: 150 issue: 1 year: 2018 ident: 879_CR76 publication-title: BMC Med doi: 10.1186/s12916-018-1122-7 – volume: 143 start-page: 1920 issue: 6 year: 2020 ident: 879_CR80 publication-title: Brain doi: 10.1093/brain/awaa137 – ident: 879_CR19 – volume: 22 start-page: 316 issue: 6 year: 2003 ident: 879_CR28 publication-title: Neuroepidemiology doi: 10.1159/000072920 – volume-title: Advances in Neural Information Processing Systems (NIPS 2017): 4-9 December 2017; Long Beach, California, US year: 2017 ident: 879_CR44 – volume: 1 start-page: 487 issue: 4 year: 2015 ident: 879_CR65 publication-title: Alzheimers Dement (Amst) doi: 10.1016/j.dadm.2015.11.002 – volume: 27 start-page: 685 issue: 4 year: 2008 ident: 879_CR51 publication-title: J Magn Reson Imaging doi: 10.1002/jmri.21049 – ident: #cr-split#-879_CR21.1 – volume: 18 start-page: 50 issue: 1 year: 1947 ident: 879_CR50 publication-title: Ann Math Stat doi: 10.1214/aoms/1177730491 – volume: 32 start-page: e100005 issue: 2 year: 2019 ident: 879_CR72 publication-title: Gen Psychiatr doi: 10.1136/gpsych-2018-100005 – volume: 338 start-page: 467 year: 2009 ident: 879_CR5 publication-title: BMJ doi: 10.1136/bmj.b158 – ident: 879_CR84 doi: 10.1101/2019.12.12.874784 – volume: 7 start-page: 107964 year: 2019 ident: 879_CR24 publication-title: IEEE Access doi: 10.1109/ACCESS.2019.2932769 – volume: 430-431 start-page: 65 year: 2018 ident: 879_CR26 publication-title: Inf Sci (N Y) doi: 10.1016/j.ins.2017.11.036 – volume-title: Outlier analysis year: 2017 ident: 879_CR16 doi: 10.1007/978-3-319-47578-3 – volume: 26 start-page: 9 issue: 1 year: 2012 ident: 879_CR58 publication-title: Brain Topogr doi: 10.1007/s10548-012-0246-x – volume: 3 start-page: CD010783 year: 2015 ident: 879_CR71 publication-title: Cochrane Database Syst Rev – volume: 194 start-page: 7 issue: 1 year: 2011 ident: 879_CR64 publication-title: Psychiatry Res Neuroimaging doi: 10.1016/j.pscychresns.2011.06.014 – ident: #cr-split#-879_CR15.1 – volume: 10 start-page: 1379 issue: 5 year: 2020 ident: 879_CR83 publication-title: WIREs Data Min Knowl Disc doi: 10.1002/widm.1379 – volume: 13 start-page: 64 issue: 1 year: 2018 ident: 879_CR3 publication-title: Mol Neurodegener doi: 10.1186/s13024-018-0299-8 – volume-title: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD 2016): 13-17 August 2016; San Francisco, California, US year: 2016 ident: 879_CR43 doi: 10.1145/2939672.2939785 – ident: 879_CR38 doi: 10.1109/CVPR.2017.369 – volume: 183 start-page: 504 year: 2018 ident: 879_CR75 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2018.08.042 – volume-title: Contributions to the Theory of Games year: 1953 ident: 879_CR36 doi: 10.1515/9781400881970-018 – volume: 33 start-page: 341 issue: 3 year: 2002 ident: 879_CR56 publication-title: Neuron doi: 10.1016/S0896-6273(02)00569-X – volume: 19 start-page: 15 issue: 1 year: 1977 ident: 879_CR41 publication-title: Technometrics doi: 10.2307/1268249 – volume: 42 start-page: 2734 issue: 9 year: 2021 ident: 879_CR12 publication-title: Hum Brain Mapp doi: 10.1002/hbm.25398 – volume: 115 start-page: 211 issue: 3 year: 2015 ident: 879_CR33 publication-title: Int J Comput Vis doi: 10.1007/s11263-015-0816-y – volume: 8 start-page: 11258 issue: 1 year: 2018 ident: 879_CR67 publication-title: Sci Rep doi: 10.1038/s41598-018-29295-9 – volume: 144 start-page: 212 issue: 2 year: 2002 ident: 879_CR86 publication-title: Am Heart J doi: 10.1067/mhj.2002.123579 – volume: 31 start-page: 968 issue: 3 year: 2006 ident: 879_CR55 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2006.01.021 – volume: 70 start-page: 1373 year: 2021 ident: 879_CR32 publication-title: J Artif Intell Res doi: 10.1613/jair.1.12125 – volume: 16 start-page: 391 issue: 3 year: 2020 ident: 879_CR1 publication-title: Alzheimers Dement doi: 10.1002/alz.12068 – ident: #cr-split#-879_CR21.2 – volume: 18 start-page: 270 issue: 4 year: 2004 ident: 879_CR88 publication-title: Alzheimer Dis Assoc Disord – ident: 879_CR14 doi: 10.1109/IJCNN.2011.6033571 – volume: 11 start-page: 8366 issue: 1 year: 2021 ident: 879_CR37 publication-title: Sci Rep doi: 10.1038/s41598-021-87762-2 – volume: 12 start-page: 2825 year: 2011 ident: 879_CR59 publication-title: J Mach Learn Res – volume: 22 start-page: 1754 issue: 4 year: 2004 ident: 879_CR73 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2004.03.040 – volume: 62 start-page: 774 issue: 2 year: 2012 ident: 879_CR54 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2012.01.021 – volume: 7 start-page: 280 issue: 3 year: 2011 ident: 879_CR4 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2011.03.003 – volume: 261 start-page: 921 issue: 5123 year: 1993 ident: 879_CR68 publication-title: Science doi: 10.1126/science.8346443 – volume: 13 start-page: 87 issue: 1 year: 2018 ident: 879_CR25 publication-title: Brain Imaging Behav doi: 10.1007/s11682-018-9831-2 – volume: 11 start-page: 367 issue: 3 year: 2020 ident: 879_CR78 publication-title: EPMA J doi: 10.1007/s13167-020-00216-z – volume: 521 start-page: 436 issue: 7553 year: 2015 ident: 879_CR35 publication-title: Nature doi: 10.1038/nature14539 – volume: 61 start-page: 1402 issue: 4 year: 2012 ident: 879_CR57 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2012.02.084 – volume-title: Proceedings of the 2016 Conference of the North American Chapter of the Association for Computational Linguistics: Demonstrations (NAACL 2016): 12-17 June 2016; San Diego, California, US year: 2016 ident: 879_CR60 doi: 10.18653/v1/n16-3020 – volume: 74 start-page: 201 issue: 3 year: 2010 ident: 879_CR27 publication-title: Neurology doi: 10.1212/WNL.0b013e3181cb3e25 – volume-title: Python 3 Reference Manual year: 2009 ident: 879_CR40 – volume: 82 start-page: 1149 issue: 10 year: 2011 ident: 879_CR70 publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp.2010.231555 – volume: 7 start-page: 14 issue: 3 year: 2016 ident: 879_CR17 publication-title: ACM J Data Inf Qual doi: 10.1145/2950109 – volume-title: Proceedings of the Information Processing in Medical Imaging (IPMI 2017): 25-30 June 2017: Boone, North Carolina, US year: 2017 ident: 879_CR22 doi: 10.1007/978-3-319-59050-912 – volume: 59 start-page: 1359 issue: 4 year: 2017 ident: 879_CR77 publication-title: J Alzheimers Dis doi: 10.3233/JAD-170261 – ident: 879_CR34 doi: 10.1109/CVPR.2016.90 – volume: 21 start-page: 672 issue: 4 year: 2009 ident: 879_CR45 publication-title: Int Psychogeriatr doi: 10.1017/S1041610209009405 – ident: 879_CR23 – volume: 7 start-page: 45269 issue: 1 year: 2017 ident: 879_CR30 publication-title: Sci Rep doi: 10.1038/srep45269 – volume: 8 start-page: 1 issue: 6 year: 2013 ident: 879_CR66 publication-title: PLoS ONE doi: 10.1371/journal.pone.0066367 – volume: 15 start-page: 1 issue: 9 year: 2020 ident: 879_CR79 publication-title: PLoS ONE doi: 10.1371/journal.pone.0236868 – volume: 10 start-page: 519 issue: 1 year: 2018 ident: 879_CR8 publication-title: Alzheimers Dement (Amst) doi: 10.1016/j.dadm.2018.07.004 – volume: 6 start-page: 212 issue: 3 year: 2010 ident: 879_CR52 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2010.03.004 – ident: 879_CR48 |
SSID | ssj0066284 |
Score | 2.4387574 |
Snippet | For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will... Background For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI) subjects will... Abstract Background For the recruitment and monitoring of subjects for therapy studies, it is important to predict whether mild cognitive impaired (MCI)... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 155 |
SubjectTerms | ADNI AIBL Alzheimer Disease - diagnostic imaging Alzheimer Disease - genetics Alzheimer's disease Australia Biomarkers Classification Cognitive ability Cognitive Dysfunction - diagnostic imaging Computer-aided medical diagnosis Data Analysis Data mining Data Shapley Datasets Dementia Diagnosis Discriminant analysis Game theory Humans Interpretability Machine Learning Magnetic Resonance Imaging Methods Neural networks Noise Older people Shapley values |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT70gEAUCpRgJiQOKGie2Yx-3QFUhwQUq9WbZjtNdaZutmuyFE1cegdfjSZhxvNFGSHDhtNJ6Im3mf7wz3xDyWiFKua1t3rRM5Lxp61xDGp-Xrat5y4OtLM47f_osLy75xytxtbfqC3vCRnjgkXGnQgUo_kTDaiW5CMIGJaRzzDLdQGhp0PtCzNsVU6MPlhK87m5ERsnTnlUsTiJD6VyoWud8FoYiWv-fPnkvKM0bJvci0PkDcj-ljnQx_uSH5F7oHpEf7-1gqU3QIhSvVemXpb0FW6cI5B16CmkptdthE8FZab91ePVC-7gAB6RCVx1drL8tw-om3P36_rOn6U8bit2jQDf0FLvjr-lqalB060BvYhtmoGnvxPURuTz_8PXdRZ7WK-ReaD7koWJNaIMuSyZbyOOshw_h0S6dAxEGBeG7xqshBHDhCAQjtfdc2NKzwhbVY3LQbbrwlNDGO-llKFwlHYeCUjeldErZUlZONYXLCNtx2_iEPY4rMNYm1iBKmlFCBiRkooQMz8jb6ZnbEXnjr9RnKMSJElGz4xegSybpkvmXLmXkJaqAGUdQJ9s3C4jo4LmU0Bl5EynQ-uEFvE1DDMAGxNGaUR7PKMFq_fx4p2YmeY3egPvkvFKK1Rl5NR3jk9gJ14XNNtJUHKepi4w8GbVyeukK98VDgZuReqavM67MT7rVMmKKK865ZOrZ_2Djc3JYRlPTORPH5GC424YXkLoN7iRa6W8tw0Jp priority: 102 providerName: Directory of Open Access Journals |
Title | Data analysis with Shapley values for automatic subject selection in Alzheimer’s disease data sets using interpretable machine learning |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34526114 https://www.proquest.com/docview/2574438817 https://www.proquest.com/docview/2573435950 https://pubmed.ncbi.nlm.nih.gov/PMC8444618 https://doaj.org/article/58eeb25d178645e5ae856bb1a19d614d |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NjtMwELZg98IFgfgLLMVISBxQtHFiO84JdcuuVkisELBSb5btuNtK3bQ06YUTVx6B1-NJmHHdsBHSnqLGE6nx_HhmMvMNIW8UopSb0qT1jImU17MyrcCNT_OZLfmMe1MY7Hf-dCHPL_nHqZjGhFsbyyr3NjEY6nrlMEd-DKLFeaEUK9-vv6c4NQq_rsYRGnfJIUKXYUlXOe0DLinB9u4bZZQ8blnBQj8yBNCZKquUDw6jgNn_v2W-cTQNyyZvnENnD8j96EDS8Y7jD8kd3zwivz6YzlATAUYoJlfp17lZg8ZThPP2LQXnlJpttwoQrbTdWkzA0DaMwQHe0EVDx8sfc7-49ps_P3-3NH66oVhDCnRdS7FG_oou-jJFu_T0OhRjehqnT1w9Jpdnp98m52kcspA6UfEu9QWr_cxXec7kDLw54-AiHGqntcBIr-AQLzFBhDAuHOFgZOUcFyZ3LDNZ8YQcNKvGPyO0dlY66TNbSMshrKzqXFqlTC4Lq-rMJoTtd1u7iECOgzCWOkQiSuodhzRwSAcOaZ6Qd_0z6x3-xq3UJ8jEnhKxs8ON1eZKR1XUQnlvc1GzUkkuvDBeCWktM6yqwVmpE_IKRUDvGlF7C6DHcK6D_VKiSsjbQIE2AF7AmdjKANuAaFoDyqMBJeiuGy7vxUxH29Hqf5KekNf9Mj6J9XCNX20DTcGxpzpLyNOdVPYvXeDUeAhzE1IO5HWwK8OVZjEPyOKKcy6Zen7733pB7uVBiaqUiSNy0G22_iW4Zp0dBf0bkcOT04vPX-DXRE5GIc3xFw5YPUA |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbK9gAXBOIvUKiRQBxQ1HViO84BoS1ttaXtCkEr9WbsxPsjbbPLZlcITlx5BF6Ch-JJmHGSpRFSbz2tFE9WiWf8ecaZ-YaQFwpZyk1iwnzIRMjzYRKm4MaH0dAmfMidiQ3WO58MZP-Mvz8X5xvkd1MLg2mVDSZ6oM5nGZ6R74BpcR4rxZK38y8hdo3Cr6tNC43KLI7ct68QspVvDvdAvy-j6GD_9F0_rLsKhJlI-TJ0Mcvd0KVRxOQQ3BeTwY_ARvXCWnhyp2DXSvBEBHlLOPKfyDTLuDBRxrqmG8P_3iCbPIZQpkM2d_cHHz422C8loH1TmqPkTsli5iugIWTvqiQNeWv7810C_t8LLm2G7UTNSzvfwR1yu3ZZaa-ysbtkwxX3yM89szTU1JQmFI9z6aexmQPGUCQQdyUFd5ia1XLmSWFpubJ45ENL33gHrIFOCtqbfh-7yYVb_Pnxq6T1xyKKWasgtywpZuWP6GSdGGmnjl749E9H634Xo_vk7FoU8IB0ilnhHhGaZ1Zm0nVtLC2HQDbNI2mVMpGMrcq7NiCsmW2d1Zzn2Hpjqn3so6SuNKRBQ9prSPOAvF7fM68YP66U3kUlriWRrdtfmC1Gul78WijnbCRylijJhRPGKSGtZYalObhHeUC20QR0Vfq6xhzdA08CEFOJNCCvvASiDrxAZuriCZgG5O9qSW61JAEtsvZwY2a6RqtS_1tbAXm-HsY7MQOvcLOVl4k5VnF3A_Kwssr1S8fYpx4C64AkLXttzUp7pJiMPZe54pxLph5f_Vjb5Gb_9ORYHx8Ojp6QW5FfUGnIxBbpLBcr9xQcw6V9Vq9GSj5fNwD8BT6Rdes |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Data+analysis+with+Shapley+values+for+automatic+subject+selection+in+Alzheimer%E2%80%99s+disease+data+sets+using+interpretable+machine+learning&rft.jtitle=Alzheimer%27s+research+%26+therapy&rft.au=Bloch%2C+Louise&rft.au=Friedrich%2C+Christoph+M&rft.au=the+Alzheimer%E2%80%99s+Disease+Neuroimaging+Initiative&rft.date=2021-09-15&rft.pub=BioMed+Central&rft.eissn=1758-9193&rft.volume=13&rft.spage=1&rft_id=info:doi/10.1186%2Fs13195-021-00879-4 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-9193&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-9193&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-9193&client=summon |